Holen Sie sich die Stockscreener-App
3.09
0.65%
0.02
Handel nachbörslich:
3.18
0.09
+2.91%
Schlusskurs vom Vortag:
$3.07
Offen:
$3.14
24-Stunden-Volumen:
1.35M
Relative Volume:
1.33
Marktkapitalisierung:
$234.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.62M
KGV:
-5.1985
EPS:
-0.5944
Netto-Cashflow:
$-62.34M
1W Leistung:
+14.02%
1M Leistung:
+11.15%
6M Leistung:
+8.04%
1J Leistung:
+9.19%
1-Tages-Spanne:
$3.08
$3.28
1-Wochen-Bereich:
$2.73
$3.28
52-Wochen-Spanne:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.09 | 232.86M | 0 | -45.62M | -62.34M | -0.5944 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
After islet transplants, 10 diabetes patients stopped using insulin - Stock Titan
Eledon Pharmaceuticals Inc (2TK.SG) - Yahoo! Finance Canada
ELDN Forecast, Price Target & Analyst Ratings | ELEDON PHARMACEUTICALS INC (NASDAQ:ELDN) - ChartMill
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3% - MarketBeat
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Geopolitics Watch: What hedge funds are buying Eledon Pharmaceuticals Inc2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Eledon (ELDN) showing 0 shares - Stock Titan
What is Noble Financial's Forecast for ELDN Q1 Earnings? - MarketBeat
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans? - Sahm
Midday Stock Roundup: RxSight Climbs 7% - Orange County Business Journal
Eledon Unveils New Type 1 Diabetes Data - Orange County Business Journal
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 2TK | US28617K1016 - marketscreener.com
If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN) - Stock Titan
Eledon Pharmaceuticals, Inc. 2026 Annual Report: Business Overview, Risk Factors, and Strategic Focus on Immunology and Tegoprubart Development 29 - Minichart
Eledon Pharmaceuticals Reports Positive 2025 Results for Tegoprubart in Transplant Trials and Receives FDA Orphan Drug Designation - Minichart
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Eledon’s Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize
Leerink Partners reiterates Outperform on Eledon stock at $5 By Investing.com - Investing.com Canada
Eledon announces updated data from investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes at UChicago Medicine - marketscreener.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine - Bitget
Eledon reports insulin independence in islet transplant trial - Investing.com
Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - Bitget
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eledon Pharmaceuticals Inc-Aktie (ELDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):